Ultrasound Committee Activities

Anthony E. Samir MD MPH
Clinical Director
MGH/MIT Center for Ultrasound Research & Translation

Disclosures

- Grant Support
  - Harvard Catalyst: Pilot Grant (NIBIB subcontract)
  - American Institute of Ultrasound in Medicine
  - MGH: Clinical Innovation Award
  - American Roentgen Ray Society: ARRS Scholarship 2011-2013
  - NIBIB subcontract via RSNA/QIBA 2013-
  - Partners Innovation Development Grant 2014-

- Research support (equipment):
  - Supersonic Imagine, General Electric, Hitachi, Toshiba, Siemens

- Consulting (via MGH)
  - Multiple CROs
Premise

• Variation in clinical practice results in poorer outcomes and higher costs.
• One approach to reduce variability in radiology is to extract objective, quantitative data from scans.

Why Must Imaging Become More Quantitative?

• Molecular medicine (precision medicine) requires quantitative test results.
• Evidence-based medicine & QA Programs depend on objective data.
• Decision-support tools (CADx, CDSS) need quantitative input.
RSNA’s Perspective:

- Extracting objective, quantitative results from imaging studies will improve the value of imaging in clinical practice.

QIBA

- **Mission**: To improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.
- **Relevance to ultrasound**:
  - US data acquisition is subject to operator-related variability
  - Acquired US data is complex and influenced by attenuation, refraction, reflections, tissue properties, temperature etc.
QIBA Criteria for Biomarker Selection

- **Transformational**
  - addresses a significant medical need
- **Translational**
  - will likely result in significant improvement in the development, approval, or delivery of care to patients.
- **Feasible**
  - end goals can likely be achieved in a specific timeframe
- **Practical**
  - leverages preexisting resources (e.g., intellectual capital, personnel, facilities, specimens, reagents, data) wherever possible; warrants access to RSNA resources and support.
- **Collaborative**
  - the biomarker has the support of the stakeholder community and the organizational impetus to sustain continued efforts.

Ultrasound Biomarker: SWS

- **Tissue shear wave speed**
- **What is elastography?**
- **Why is elastography transformational?**
Chronic Liver Disease (CLD):

- Toxic, metabolic, immune and infectious diseases that damage the liver.
- Repeated cycles of tissue damage and healing produce the “common pathway” progression of liver fibrosis to cirrhosis.
- Substantial morbidity worldwide with huge economic burden.
- Prognosis and management greatly depends on the degree of liver fibrosis.

Chronic Hepatitis B Epidemiology

- Worldwide prevalence of HBV infection is ~ 2 billion, with 350 million suffering from CHB
- Over 1 M adult with CHB in the USA with estimated 2000 to 4000 deaths annually.
- Mainland China has one of the highest carrier prevalences in the world (nearly 10% of general population).
Chronic Hepatitis C Epidemiology

- Worldwide prevalence of HCV infection is 170-200 M.
- Prevalence of HCV in the USA is around 2-3 M. HCV prevalence in Mainland China is also substantial (estimated 3.2% of general population)
- Rate of cirrhosis in HCV: 10% in 20 years and 20% in 30 years.
- Mortality in cirrhotic: 1-5 % per year.
- HCC in cirrhotic: 1-4% per year.


Nonalcoholic Fatty Liver Disease (NAFLD):

- NAFLD is no longer a disease exclusive to developed Western countries. It should be regarded as a global problem. Among more affluent regions of China, its prevalence is ~15%.
- May progress to NASH in a minority, with risk of cirrhosis.
- Prognosis strongly depends on histologic severity.

[The Spectrum of NAFLD](http://next-level-nutrition.com/?p=1448)

Next Level Nutrition
Liver Biopsy, Imperfect Reference Standard

- Liver biopsy (LB) is the reference standard for Liver fibrosis (LF) staging.

Advantages:
- Provides information about necrosis, inflammation, steatosis, siderosis

Limitations:
- Invasive:
  - Transient pain, anxiety and discomfort (30%)
  - Bleeding in 0.3%, mortality in 0.01%
- Inaccurate:
  - Sampling error (1/50,000th of the liver sampled)
  - Intra- and inter-observer variability (pathologist expertise)
- Qualitative
- Expensive

Surrogate Fibrosis Markers

- Initially studied in CHC but now increasingly used in CHB, NAFLD, alcoholic hepatitis.
- Combining surrogate makers with LB could provide better information than LB alone.

1. Serum Biomarkers of LF
2. Non-invasive Imaging-Based Methods
Imaging Modalities

- Conventional imaging: Ultrasound, CT or MRI.
  - High specificity for identification advanced LF and sign of portal hypertension
  - Low sensitivity for early LF.
- MR Elastography
  - Advantages:
    - Assess the entire liver parenchyma, operator independent, no acoustic window required.
    - MRI techniques may also aid in quantifying hepatic fat content.
  - Disadvantages:
    - Costly, longer acquisition time
    - Iron overload can confound
- Sonoelastography

Introduction - Elastography

What is Elastography?
Imaging techniques that evaluate the mechanical characteristics of tissue, with the objective of deriving estimates of tissue deformability in response to compressive forces.

Why is Elastography Potentially Useful?
Pathologic processes alter tissue structure, which alters tissue mechanics: examples – increased stiffness of the fibrotic liver, breast lumps, prostate nodules.

Elasticity
It is a biomechanical property of any material that deforms reversibly under an applied stress.

Tissue elasticity
is characterized by the amount of tissue displacement in response to the application of an external force.
Physical Principles: Key Concepts

• **Stress**: The force divided by the cross-sectional area. (Unit is kPa).

\[
\text{Stress, } \sigma = \frac{\text{Force}}{\text{Cross-Sectional Area}} = \frac{F}{A_0}
\]

• **Strain**: Deformation quantified as relative displacement of particles in the material. (No unit)

Elastic Modulus

The description of a material’s tendency to be non-permanently deformed under stress. It can be depicted on a stress-strain curve.

Principles of ultrasound elastography, Peter R Hoskins, Ultrasound February 2012 vol. 20 no. 1 8-15
Young’s Modulus (Tensile Modulus)

Young’s Modulus = $E = \text{Stress}/\text{Strain}$

Every material has a specific Young’s modulus. Values for healthy soft tissues (liver, prostate, kidney and breast) range from 0.5-70 kPa, whereas the Young’s modulus of cancer is typically higher, ranging from 20-560 kPa.

Steps in the Estimation of Elastic Modulus in Shear Wave Sonoelastography:

- Induce shear waves
- Measure shear wave speed
- Estimate the tissue stiffness & differentiate normal from pathologic tissues

This velocity is directly related to tissue stiffness. The harder the tissue, the faster the shear wave propagates.
Acoustic Radiation Force Impulse (ARFI) Imaging

- Integrated into conventional US transducers.
- High energy short duration (< 1ms) acoustic waves induce focal micro SW (1-20 µm) in a ROI.
- Shear wave speed is related to tissue elasticity, permitting quantitation of Young’s modulus.
- Mean ARFI values were significantly lower in Asian than in European patients in cases with mild fibrosis (F1), to (F3) and (F4).

Advantages of ARFI:

- Not confounded by high BMI, subcutaneous fat, ascites.
- Can detect focal lesions – mechanical contrast.
- For the same stage of fibrosis the mean values by ARFI are similar for CHC and CHB.
Real-Time Shear Wave Elastography (SWE):

- An advanced technique combining real time imaging with true quantitation.
- Currently implemented on the Supersonic Aixplorer.
- Color coded elasticity estimates are displayed in real time in an image box superimposed on a conventional B-mode image.
- This image box can be moved to avoid artifacts beneath liver capsule and pulsation around larger vessels.
- A circular ROI can be placed to estimate the elasticity mean & SD.
- Real time SWE is subject to the same limitations of conventional US imaging: user dependent and patient body habitus.

MGH Liver Fibrosis Study:

- Differentiation of mild (F0, F1) fibrosis from significant fibrosis (F2, F3, F4) had an AUROC of 0.72 (95%CI: 0.61-0.84).
- The highest AUROC was achieved with measurements in the RLL.
- At a cut off >7.6 kPa (sensitivity 72%, specificity 60%).

- The diagnostic accuracy of SWE for liver fibrosis staging in MGH CHC patients MGH is:
  - For F ≥ 2: AUROC= 0.72
  - For F ≥ 3: AUROC= 0.74
  - For F =4: AUROC= 0.98

<table>
<thead>
<tr>
<th>Total number of Subjects (n)</th>
<th>110</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean age, range)</td>
<td>49 (18-79)</td>
</tr>
<tr>
<td>Gender</td>
<td>55 males; 55 females</td>
</tr>
<tr>
<td>Fibrosis Stage (n, Percentage)</td>
<td></td>
</tr>
<tr>
<td>F0</td>
<td>13 (11.8%)</td>
</tr>
<tr>
<td>F1</td>
<td>68 (61.8%)</td>
</tr>
<tr>
<td>F2</td>
<td>13 (11.8%)</td>
</tr>
<tr>
<td>F3</td>
<td>9 (8.2%)</td>
</tr>
<tr>
<td>F4</td>
<td>7 (6.4%)</td>
</tr>
</tbody>
</table>
Detection of Portal Hypertension and Esophageal Varices

**PH & EV:**
- Estimated prevalence of EV in cirrhotic patients: 50%  
- Mortality rate of VB ranges from 20% to 35%.  
- American and European guidelines recommend screening of upper GI endoscopy for early detection of EV in all patients with compensated cirrhosis.  
- Effective prophylactic treatment (β-blocker) of EV in decompensated cirrhosis:
  - Improve patient prognosis.  
  - Reduce hospitalization cost.
Portal Hypertension Assessment:
Reference Standards:

- Measurement of Hepatic Venous Pressure Gradient (HVPG) for PH assessment:
  1. Clinical significant HVPG for PH ≥ 10 mmHg: development of gastroesophageal fibrosis.
  2. Severe HVPG ≥ 12 mmHg is threshold for hepatic decompensation: variceal bleeding, ascites, encephalopathy and renal failure.

- Upper GI endoscopy for risk assessment of esophageal varices bleeding in cirrhotic patients.

- Both are invasive, expensive, and HVPG measurement is routinely available only in expert centers.

- We need noninvasive methods with acceptable diagnostic accuracy to predict clinical outcomes in cirrhotic pts. with low risk of complications to avoid unnecessary endoscopy or prophylactic treatment.

PH and EV Assessment By ARFI:

- Spleen stiffness measurement by ARFI has excellent diagnostic performance for predicting EV and the severity of EV, regardless of the severity and etiology of cirrhosis.

- SS cut-off value: 3.18 m/s identifies pts. with EV: Sen:98.5%, NPV: 98.4%

- SS cut-off value: 3.30 m/s identifies high risk pts. : Sen: 98.9% NPV: 99.4% & accuracy: 72.1%

- Higher success rate (2.8%) than TE (14.6%) for measuring SS.

- The inter-observer agreement ICC on SS :0.98 (95% CI 0.95 to 0.99)

- The intra-observer agreement ICC on SS: 0.98 (95% CI 0.96 to 0.99)
QIBA: US Activities

- Technical and Clinical Subcommittees
  - Technical subcommittee focuses on sources of variability originating within the equipment chain.
  - Clinical subcommittee focuses on sources of variability originating within clinical data acquisition and interpretation.

- Phantom construction
  - Simple linear phantoms
  - Nonlinear phantoms approximating tissue (2014)

- Simulations
- Clinical guidelines
  - Elastography case report forms (version 5)
  - Pathology case report forms (version 2)

- UPICT protocol
- QIDW uploads
MGH Clinical Ultrasound Research Fellowship

- 1-2 years of customizable practical research experience and coursework and clinical observation.

Manish Dhyani M.D.
Research Fellow

Priyanush Kandakatla M.D.
Research Fellow

Arash Anvari M.D.
Research Fellow

Qingli Zhu M.D.
Research Fellow

THANK YOU